Immunovant, Inc. (IMVT) News
Filter IMVT News Items
IMVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMVT News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IMVT News From Around the Web
Below are the latest news stories about IMMUNOVANT INC that investors may wish to consider to help them evaluate IMVT as an investment opportunity.
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Immunovant price target lowered to $45 from $47 at Wells FargoWells Fargo analyst Derek Archila lowered the firm’s price target on Immunovant (IMVT) to $45 from $47 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks |
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against the other biotech stocks. Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth Biotechnology stocks are among the most volatile in the market due […] |
Q2 2024 Roivant Sciences Ltd Earnings CallQ2 2024 Roivant Sciences Ltd Earnings Call |
Immunovant's Q2 Loss Wider Than Expected, Pipeline in FocusIMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications. |
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rh |
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingNEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting b |
Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?We recently compiled a list of 10 Worst Performing Stocks to Buy on the Dip. In this article, we will look at where Immunovant, Inc. (NASDAQ:IMVT) ranks among the worst performing stocks to buy on the dip. Capital markets demonstrated increased volatility starting in August 2024 and continuing in September 2024. That being said, strong […] |
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?We recently made a list of the 10 Best NASDAQ Stocks Under $50 to Buy. In this piece, we will look at where Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best NASDAQ stocks under $50 to buy. The close of 2024’s third quarter is seeing Wall Street rejoice as the Federal Reserve finally delivers its […] |
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. Immunovant is a member of the Roivant Sciences Ltd. (NASDAQ:ROIV) family of companies. Also Read: Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study. As previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves’ Disease enrolled p |